^
Association details:
Biomarker:Chr t(14;16)
Cancer:Multiple Myeloma
Regimen:DVD (bortezomib + Darzalex (daratumumab) + dexamethasone injection)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Published date:
08/20/2020
Excerpt:
High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities....Among a subset of patients who had received 1 prior line of therapy, treatment with D-Vd prolonged median PFS versus Vd in patients with standard cytogenetic risk (29.8 months vs 7.5 months; HR, 0.25; 95% CI, 0.15–0.42; P < 0.0001; Fig. 1c) and high cytogenetic risk (20.1 months vs 8.4 months; HR, 0.20; 95% CI, 0.06–0.62; P = 0.0026...
DOI:
10.1186/s13045-020-00948-5
Trial ID: